This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
FSHB · Western blot design guide
FSHB Western Blot Planning Guide
Plan a FSHB Western blot around the catalog-observed 14.7 kDa band, image-backed PB9106 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
FSHB Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 14.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Pituitary gland | |
| Negative control | Appendix |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 14.7 kDa |
| ⓘ | Localization | Secreted |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse |
Section 1
Real Curated FSHB Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Pituitary gland |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9106 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected FSHB Western Blot Band Size?
Use the product-observed 14.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 14.7 kDa | Matches the authoritative product WB observation. |
| 14.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected FSHB appearancePlan around 14.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 14.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 14.7 kDa from UniProt P01225; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9106. |
| Situation | Likely cause | Next action |
|---|---|---|
| 14.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing FSHB band
PB9106 · FSHB
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for FSHB Western blot
🧪Use Pituitary gland as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Pituitary gland (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for FSHB
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Pituitary gland | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced FSHB Western Blot Tips
Deeper troubleshooting and optimisation questions for FSHB, answered from its protein features.
Which band should guide the blot?
Use 14.7 kDa, the observation attached to the authoritative PB9106 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 14.7 kDa expectation.
Which positive control should I start with?
Start with Pituitary gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for FSHB Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9106 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
FSHB Western Blot Reagents
Human/Mouse-reactive FSHB Western blot reagents with authoritative product imagery.
Real WB data
Anti-FSH beta/FSHB Antibody Picoband®
Cat # PB9106
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P01225
- Human Protein Atlas — FSHB
- PB9106 product record
- PMC10486264 — Establishment of cell-lines stably expressing recombinant Japanese eel follicle-stimulating hormone and luteinizing hormone using CHO-DG44 cells: fully induced ovarian development at different modes (Frontiers in endocrinology, 2023)
- PMC5338029 — The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways (Scientific reports, 2017)
